RGNX
Neutral signalScored 2026-09-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
REGENXBIO Inc.
- Nom
- REGENXBIO Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $441.0M
- Employés
- 371
- PDG
- Curran Simpson
- Site web
- https://www.regenxbio.com
- Marché
- FDMTGNPXLXEOMGTXOCGNPGEN
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 102 603 titres (~949 381,45 $ US)
- Insiders
- Ciongoli Gregory Austin
- Total bought
-
$949,381
Avg buy (VWAP, 90d window) $9.25 vs last close $7.40 (-20.0%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-27
- Liquidity
- Thin $9,789,728/day · 20d vol
- Last synced
-
2026-09-25 21:10:51
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-27 | Ciongoli Gregory Austin | Buy · P | 53,407 | $9.36 | $499,676 | Form 4 |
| 2026-08-26 | Ciongoli Gregory Austin | Buy · P | 49,196 | $9.14 | $449,706 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-11-08 | Peter Welch | Sale (Full) | $1,001 - $15,000 |
| 2019-10-22 | Peter Welch | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
RGNX presents a deeply unfavorable risk/reward profile: weak liquidity (45) and deteriorating fundamentals (25) are compounded by a high debt-to-equity of 2.54 and persistent cash burn with no path to near-term…
The first sentence of the analysis written for RGNX on 2026-09-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.38 · operating margin -95% — readings disagree
Suggested stop 5.23, nearest stored support minus 0.5 ATR(29.4% under the last close). Reward/risk to the next stored resistance is 0.59. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 88.1% | 59.7% | 58.8% | 51.6% | 89.0% | |
| Ebit Margin | -87.3% | -257.3% | -284.6% | -228.1% | 35.6% | |
| Ebitda Margin | -78.2% | -237.9% | -265.4% | -216.7% | 37.7% | |
| Operating Profit Margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | |
| Pretax Profit Margin | -113.8% | -272.5% | -292.2% | -248.8% | 30.0% | |
| Continuous Operations Profit Margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | |
| Net Profit Margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | |
| Bottom Line Profit Margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | |
| Current Ratio | 2.382 | 2.694 | 2.571 | 3.189 | 3.977 | |
| Quick Ratio | 2.382 | 2.694 | 2.571 | 3.189 | 3.977 | |
| Solvency Ratio | -0.509 | -1.022 | -0.939 | -0.843 | 0.393 | |
| Cash Ratio | 0.292 | 0.557 | 0.265 | 0.743 | 2.646 | |
| Price To Earnings Ratio | -3.830 | -1.684 | -2.982 | -3.489 | 10.864 | |
| Price To Earnings Growth Ratio | 0.212 | 0.071 | 0.404 | 0.011 | -0.054 | |
| Forward Price To Earnings Growth Ratio | 0.212 | 0.071 | 0.404 | 0.011 | -0.054 | |
| Price To Earnings Diluted Ratio | -3.830 | -1.684 | -2.982 | -3.489 | 11.237 | |
| Price To Earnings Diluted Growth Ratio | 0.212 | 0.071 | 0.404 | 0.011 | -0.057 | |
| Price To Book Ratio | 7.229 | 1.474 | 2.518 | 1.896 | 1.816 | |
| Price To Sales Ratio | 4.357 | 4.593 | 8.699 | 8.682 | 2.950 | |
| Price To Free Cash Flow Ratio | -5.876 | -2.180 | -3.438 | -4.108 | 10.302 | |
| Price To Operating Cash Flow Ratio | -5.991 | -2.211 | -3.594 | -4.717 | 6.340 | |
| Debt To Assets Ratio | 0.575 | 0.176 | 0.156 | 0.114 | 0.078 | |
| Debt To Equity Ratio | 2.536 | 0.316 | 0.286 | 0.184 | 0.113 | |
| Debt To Capital Ratio | 0.717 | 0.240 | 0.223 | 0.155 | 0.102 | |
| Long Term Debt To Capital Ratio | 0.589 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 4.410 | 1.795 | 1.841 | 1.614 | 1.457 | |
| Working Capital Turnover Ratio | 1.009 | 0.439 | 0.368 | 0.335 | 1.122 | |
| Operating Cash Flow Ratio | -1.050 | -1.678 | -1.677 | -1.591 | 1.678 | |
| Operating Cash Flow Sales Ratio | -0.727 | -2.078 | -2.420 | -1.841 | 0.465 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.014 | 1.046 | 1.148 | 0.615 | |
| Debt Service Coverage Ratio | -1.434 | -15.659 | -34.875 | -10.500 | 6.229 | |
| Interest Coverage Ratio | -3.582 | -18.433 | -39.074 | -11.305 | 6.088 | |
| Short Term Operating Cash Flow Coverage Ratio | -2.588 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.476 | -2.110 | -2.446 | -2.189 | 2.525 | |
| Capital Expenditure Coverage Ratio | -51.352 | -71.069 | -21.928 | -6.753 | 2.600 | |
| Dividend Paid And Capex Coverage Ratio | -51.352 | -71.069 | -21.928 | -6.753 | 2.600 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.270 | -2.054 | -3.507 | -3.998 | 6.376 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 88.1% | ▲28.4% | ▲18.7% |
| Ebit Margin | -87.3% | ▲170.0% | ▲77.0% |
| Ebitda Margin | -78.2% | ▲159.7% | ▲73.9% |
| Operating Profit Margin | -94.6% | ▲185.5% | ▲79.6% |
| Pretax Profit Margin | -113.8% | ▲158.8% | ▲65.7% |
| Continuous Operations Profit Margin | -113.8% | ▲158.8% | ▲66.2% |
| Net Profit Margin | -113.8% | ▲158.8% | ▲66.2% |
| Bottom Line Profit Margin | -113.8% | ▲158.8% | ▲66.2% |
| Current Ratio | 2.382 | ▼-0.312 | ▼-0.581 |
| Quick Ratio | 2.382 | ▼-0.312 | ▼-0.581 |
| Solvency Ratio | -0.509 | ▲0.513 | ▲0.075 |
| Cash Ratio | 0.292 | ▼-0.266 | ▼-0.609 |
| Price To Earnings Ratio | -3.830 | ▼-2.146 | ▼-3.606 |
| Price To Earnings Growth Ratio | 0.212 | ▲0.141 | ▲0.083 |
| Forward Price To Earnings Growth Ratio | 0.212 | ▲0.141 | ▲0.083 |
| Price To Earnings Diluted Ratio | -3.830 | ▼-2.146 | ▼-3.680 |
| Price To Earnings Diluted Growth Ratio | 0.212 | ▲0.141 | ▲0.084 |
| Price To Book Ratio | 7.229 | ▲5.755 | ▲4.242 |
| Price To Sales Ratio | 4.357 | ▼-0.235 | ▼-1.499 |
| Price To Free Cash Flow Ratio | -5.877 | ▼-3.697 | ▼-4.816 |
| Price To Operating Cash Flow Ratio | -5.991 | ▼-3.780 | ▼-3.956 |
| Debt To Assets Ratio | 0.575 | ▲0.399 | ▲0.355 |
| Debt To Equity Ratio | 2.536 | ▲2.220 | ▲1.849 |
| Debt To Capital Ratio | 0.717 | ▲0.477 | ▲0.430 |
| Long Term Debt To Capital Ratio | 0.589 | ▲0.589 | ▲0.471 |
| Financial Leverage Ratio | 4.410 | ▲2.615 | ▲2.186 |
| Working Capital Turnover Ratio | 1.008 | ▲0.569 | ▲0.354 |
| Operating Cash Flow Ratio | -1.050 | ▲0.628 | ▼-0.186 |
| Operating Cash Flow Sales Ratio | -0.727 | ▲1.350 | ▲0.593 |
| Free Cash Flow Operating Cash Flow Ratio | 1.020 | ▲0.005 | ▲0.051 |
| Debt Service Coverage Ratio | -1.434 | ▲14.225 | ▲9.813 |
| Interest Coverage Ratio | -3.582 | ▲14.852 | ▲9.680 |
| Short Term Operating Cash Flow Coverage Ratio | -2.588 | ▼-2.588 | ▼-2.071 |
| Operating Cash Flow Coverage Ratio | -0.476 | ▲1.635 | ▲0.463 |
| Capital Expenditure Coverage Ratio | -51.352 | ▲19.718 | ▼-21.651 |
| Dividend Paid And Capex Coverage Ratio | -51.352 | ▲19.718 | ▼-21.651 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.269 | ▼-5.215 | ▼-5.179 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $742.7M | $382.7M | $785.0M | $978.7M | $1.39B | |
| Enterprise value | $968.7M | $407.2M | $839.8M | $976.5M | $1.13B | |
| EV / Sales | 5.68x | 4.89x | 9.31x | 8.66x | 2.40x | |
| EV / Op. cash flow | -7.81x | -2.35x | -3.85x | -4.71x | 5.16x | |
| EV / Free cash flow | -7.67x | -2.32x | -3.68x | -4.10x | 8.38x | |
| EV / EBITDA | -7.27x | -2.05x | -3.51x | -4.00x | 6.38x | |
| Net debt / EBITDA | -1.70x | -0.12x | -0.23x | 0.01x | -1.46x | |
| Current ratio | 2.38x | 2.69x | 2.57x | 3.19x | 3.98x | |
| Income quality | 0.64x | 0.76x | 0.83x | 0.74x | 1.71x | |
| Graham number | — | — | — | — | $35 | |
| Graham net-net | -$2 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 99.9% | 100.0% | 90.5% | |
| Interest burden | 130.2% | 105.9% | 102.7% | 109.0% | 84.3% | |
| Working capital | $163.2M | $174.8M | $204.7M | $285.5M | $388.4M | |
| Invested capital | $315.2M | $346.1M | $397.3M | $492.3M | $580.8M | |
| Return on assets | -42.8% | -48.7% | -45.9% | -33.6% | 11.5% | |
| Operating ROA | -35.1% | -44.9% | -38.1% | -27.0% | 17.6% | |
| Return on tangible assets | -42.8% | -48.7% | -45.9% | -33.6% | 11.5% | |
| Return on equity | -188.7% | -87.5% | -84.5% | -54.3% | 16.7% | |
| Return on invested capital | -42.1% | -62.9% | -59.4% | -37.1% | 14.7% | |
| Return on capital employed | -48.1% | -64.3% | -60.4% | -37.4% | 16.3% | |
| Earnings yield | -26.1% | -59.3% | -33.6% | -28.6% | 9.2% | |
| Free cash flow yield | -17.0% | -45.9% | -29.1% | -24.3% | 9.7% | |
| Capex / Op. cash flow | -1.9% | -1.4% | -4.6% | -14.8% | 38.5% | |
| Capex / Depreciation | 15.5% | 15.0% | 57.5% | 238.0% | 880.1% | |
| Capex / Sales | 1.4% | 2.9% | 11.0% | 27.3% | 17.9% | |
| SG&A / Sales | 48.6% | 91.9% | 98.1% | 75.7% | 16.9% | |
| R&D / Sales | 133.9% | 250.2% | 257.4% | 215.1% | 38.6% | |
| Stock comp / Sales | 20.3% | 46.2% | 44.6% | 36.2% | 8.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 59d | 94d | 107d | 98d | 25d | |
| Days payables outstanding | 384d | 248d | 223d | 182d | 80d | |
| Operating cycle | 59d | 94d | 107d | 98d | 25d | |
| Cash conversion cycle | -325d | -153d | -117d | -84d | -55d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-25 Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its offi
- 2026-08-25 Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance reforms, the return of funds to the Company, and a court-approved incentive award, all at no cost to them. What Sho.
- 2026-08-25 RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
- 2026-08-25 Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity Regenxbio is rated a ''risky buy'' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
- 2026-08-25 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md., Aug. 25, 20
- 2026-08-25 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
- 2026-08-24 RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.
- 2026-08-24 Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company''s investigational therapy for Hunter syndome.
- 2026-08-24 FDA places clinical hold on Regenxbio''s gene therapy for Hunter Syndrome Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.
- 2026-08-24 REGENXBIO Announces Regulatory Update on RGX-121 for MPS II ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.